Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations.

Kamolpat ChaiyakittisoponOraluck PattanaprateepNarisa RuenroengbunTunlanut SapankaewAtiporn IngsathitGareth J MckayJohn AttiaAmmarin Thakkinstian

Published in: The European journal of health economics : HEPAC : health economics in prevention and care (2021)

Lanthanum carbonate was significantly more cost-effective than CBPBs as a second-line option for hyperphosphatemia in pre-dialysis patients in HICs. However, the use of sevelamer is not more cost-effective as a first-line option compared to CBPBs.

Keyphrases

end stage renal disease
chronic kidney disease
ejection fraction
peritoneal dialysis
newly diagnosed
prognostic factors
patient reported outcomes
combination therapy